The α1 and α6 subunit subtypes of the mammalian GABAA receptor confer distinct channel gating kinetics
Open Access
- 26 November 2004
- journal article
- research article
- Published by Wiley in The Journal of Physiology
- Vol. 561 (2) , 433-448
- https://doi.org/10.1113/jphysiol.2003.051839
Abstract
The GABAA receptors show a large degree of structural heterogeneity, with seven different subunit families, and 16 different subtypes in mammalian species. The α family is the largest, with six different subtypes. The α1 and α6 subtypes are among the most diverse within this family and confer distinct pharmacological properties to recombinant and neuronal receptors. To determine whether different single channel and macroscopic kinetic properties were also associated with these subtypes, the α1 or α6 subunit was expressed in mammalian cells along with β3 and γ2L subunits and the kinetic properties examined with outside-out patch recordings. The α1β3γ2L receptors responded to GABA with long-duration openings organized into multi-opening bursts. In contrast, channel openings of the α6β3γ2L receptors were predominately short in duration and occurred as isolated, single openings. The subunit subtype also affected the deactivation rate of the receptor, which was almost 2-fold slower for α6β3γ2L, compared with the α1β3γ2L isoform. Onset of fast desensitization did not differ between the isoforms. To determine the structural domains responsible for these differences in kinetic properties, we constructed six chimeric subunits, combining different regions of the α1 and α6 subunits. The properties of the chimeric subunits indicated that structures within the third transmembrane domain (TM3) and the TM3–TM4 intracellular loop conferred differences in single channel gating kinetics that subsequently affected the deactivation rate and GABA EC50. The effect of agonist concentration on the rise time of the current showed that the extracellular N-terminal domain was largely responsible for binding characteristics, while the transmembrane domains determined the activation rate at saturating GABA concentrations. This suggests that subunit structures outside of the agonist binding and pore-lining domains are responsible for the kinetic differences conferred by the α1 and α6 subtypes. Structural heterogeneity within these transmembrane and intracellular regions can therefore influence the characteristics of the postsynaptic response of GABAA receptors with different subunit composition.Keywords
This publication has 81 references indexed in Scilit:
- A mutation in the GABAA receptor α1 subunit linked to human epilepsy affects channel gating propertiesNeuropharmacology, 2004
- GABA α6 receptors mediate midazolam-induced anxiolysisJournal of Clinical Anesthesia, 2002
- Somato-synaptic variation of GABAA receptors in cultured murine cerebellar granule cells: investigation of the role of the α6 subunitNeuropharmacology, 2000
- Developmental change in GABAA receptor desensitization kinetics and its role in synapse function in rat cortical neuronsThe Journal of Physiology, 2000
- Evidence of Two Populations of GABAA Receptors in Cerebellar Granule Cells in Culture: Different Desensitization Kinetics, Pharmacology, Serine/ Threonine Kinase Sensitivity, and LocalizationBiochemical and Biophysical Research Communications, 1999
- Receptor system response kinetics reveal functional subtypes of native murine and recombinant human GABAA receptorsThe Journal of Physiology, 1999
- Spillover-Mediated Transmission at Inhibitory Synapses Promoted by High Affinity α6 Subunit GABAA Receptors and Glomerular GeometryNeuron, 1998
- Single channel properties of recombinant GABAA receptors containing γ2 or δ subtypes expressed with α1 and β3 subtypes in mouse L929 CellsThe Journal of Physiology, 1997
- Distinct Deactivation and Desensitization Kinetics of Recombinant GABAA ReceptorsNeuropharmacology, 1996
- Bi-directional changes in the levels of messenger RNAs encoding γ-aminobutyric acidA receptor α subunits after flurazepam treatmentEuropean Journal of Pharmacology: Molecular Pharmacology, 1992